Interleukin 1 (IL1) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Interleukin 1 (IL1) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Interleukin 1 (IL1) - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope:

• The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
• The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics
  

Key Topics Covered:

1. Introduction
2. Interleukin 1 (IL1) - Overview
3. Interleukin 1 (IL1) - Therapeutics Development
4. Products under Development by Stage of Development
5. Products under Development by Therapy Area
6. Products under Development by Indication
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Interleukin 1 (IL1) - Therapeutics Assessment
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Interleukin 1 (IL1) - Companies Involved in Therapeutics Development

• AbbVie Inc
• Apexigen Inc
• Exicure Inc
• Immune Response BioPharma Inc
• Moderna Therapeutics Inc
• Novartis AG
• Omnitura Therapeutics Inc
• Opsona Therapeutics Ltd
• Optimum Therapeutics LLC
• Orphit SAS
• Peptinov SAS
• Pfizer Inc
• R Pharm
• Regeneron Pharmaceuticals Inc
• Spherium Biomed SL
• Swedish Orphan Biovitrum AB
• XBiotech Inc

For more information about this report visit https://www.researchandmarkets.com/research/3fkcb3/interleukin_1